| Literature DB >> 35562380 |
Wanda G H Han1, Arno Swart1, Axel Bonačić Marinović1, Dirk Eggink1, Johan Reimerink1, Lisa A Wijsman1, Bas van der Veer1, Sharon van den Brink1, Anne-Marie van den Brandt1, Sophie van Tol1, Gert-Jan Godeke1, Fion Brouwer1, Marieke Hoogerwerf1, Daphne F M Reukers1, Nynke Rots1, Chantal Reusken1, Adam Meijer2.
Abstract
This study investigated the dynamics of SARS-CoV-2 infection and diagnostics in 242 household members of different ages and with different symptom severity after SARS-CoV-2 exposure early in the pandemic (March-April 2020). Households with a SARS-CoV-2 confirmed positive case and at least one child in the Netherlands were followed for 6 weeks. Naso (NP)- and oropharyngeal (OP) swabs, oral fluid and feces specimens were analyzed for SARS-CoV-2 RNA and serum for SARS-CoV-2-specific antibodies. The dynamics of the presence of viral RNA and the serological response was modeled to determine the sampling time-frame and sample type with the highest sensitivity to confirm or reject a SARS-CoV-2 diagnosis. In children higher viral loads compared to adults were detected at symptom onset. Early in infection, higher viral loads were detected in NP and OP specimens, while RNA in especially feces were longer detectable. SARS-CoV-2-specific antibodies have 90% probability of detection from 7 days (total Ig) and 18 days (IgG) since symptom onset. For highest probability of detection in SARS-CoV-2 diagnostics early in infection, RT-PCR on NP and OP specimens are more sensitive than on oral fluid and feces. For SARS-CoV-2 diagnostics late after infection, RT-PCR on feces specimens and serology are more valuable.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35562380 PMCID: PMC9099349 DOI: 10.1038/s41598-022-11480-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Schedule of administering questionnaires, symptom diaries and home visits for sampling.
| Day | Visit 1 | Visit 2 | Visit 3 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 (range 14–21) | 35 (range 28–42) | |
| Start questionnaire | x | |||||||||||||||
| Symptoms diary | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
| Final questionnaire | x | |||||||||||||||
| Blood (serum)—Wantai | 222 | 210 | 149 | |||||||||||||
| Blood (serum)—Microarray S1 and N | 230 | 221 | 208 | |||||||||||||
| Nasopharyngeal swab | 183a | 53 | 46 | 51 | 55 | 221 | ||||||||||
| Oropharyngeal swab | 187a | 53 | 47 | 51 | 54 | 230 | ||||||||||
| Oral fluid | 219 | 206 | 189 | |||||||||||||
| Feces | 222 | 226 | 195 | |||||||||||||
The numbers in the table indicate the amount of analysed specimens in 242 participants.
aA naso- and oropharyngeal swab was not collected for the index case at the first home visit, as these persons were already swabbed a few days before and tested SARS-CoV-2 positive.
Figure 1Various transmission patterns of SARS-CoV-2 infection based on different assays and specimen types collected at visits 1, 2 and 3 in households visualized in heatmaps. (A) households with no transmission. (B) household with only transmission in adults. (C) heatmaps of household with transmission in children and possibly also adults. Symptoms can be unrelated to a SARS-CoV-2 infection. On the left side, Male (M) or female (F) and age of the participant is indicated. * Index case. Blanks = not available/tested. Red rectangle: individual with only one test positive on one timepoint. On the right side the Household ID (number) is indicated.
Figure 2Symptom severity of COVID-19 index cases in the households. The GLM (generalized linear model) revealed that there were less individuals in the "Severe" category than in the "Mild" category (p = 0.1), and that households in "Family transmission" category was overrepresented in the "Severe" category (p = 0.03). There were no asymptomatic index cases. Maximum severity score of index is used.
Figure 3(A) Overview of the (combination of) various positive SARS-CoV-2 infection diagnosis in the 242 participants of the study cohort for all various diagnostic assays or specimens. All available RT-PCR and serology outcomes (Table 1) were incuded in these analyses.The black dots indicate a positive test at any (or multiple) moment(s) during the study, except for ‘Inclusion PCR NP + OP’ which was performed in index cases just before start of the study. The number of individuals with a particular combination of positive tests are indicated in the top of the figure. The numbers at the right after each test indicates the overall number of positive tests. (B) The number of individuals with a positive or negative tests or missing data for serological and molecular (PCR) diagnostics combined. In brackets the number of symptomatic or severe symptomatic individuals, respectively, are indicated. Color intensity is related to the frequency.
Figure 4Common SARS-CoV-2 infection dynamics patterns, based on the presence or absence of a positive or negative RT-PCR or serological assay at visit 1, 2 and 3. Common patterns were named A–F based on frequency, with the number of individuals (n) displaying the pattern indicated. The median timing of onset of symptoms relative to visit 1 is indicated on the left. The black line indicates whether on average symptoms were reported at visit 1, 2 or 3.
Figure 5Dynamics SARS-CoV-2 infection diagnosis by RT-PCR in various specimens since symptoms onset (dps). All available RT-PCR outcomes (Table 1) were incuded in these analyses. (A) Predicted viral load (Ct values RT-PCR) in relation to dps and specimen type. The shadow indicates the 95% Bayesian confidence interval and the dotted lines indicate the prediction interval (variation over individuals). (B) and (C) Ct-value distribution at day symptom onset (intercept) and increase of Ct-value per day (slope) in relation to age category (B) and different specimens (C). (D) Average dps until when different specimens have at least 90% detection probability.
Figure 6Dynamics of SARS-CoV-2 infection diagnosis by different serological assays. All available serology outcomes (Table 1) were incuded in these analyses. Probability of SARS-CoV-2-specific antibody detection (A) and average dps from when the Wantai (Spike-specific IgM and IgG), microarray S1 (Spike-specific IgG) and microarray N (Nucleoprotein-specific IgG) assays have at least 90% detection probability (B) for all ages. (C) Probability of SARS-CoV-2-specific antibody detection by Wantai, microarray S1 and microarray N in adults and children (D) Average dps from when microarray N has at least 90% detection probability for adults and children. The shadows in (C) and (D) indicate the 95% Bayesian confidence interval.